Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.50 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | FASN | P49327 | 4/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | GPR6 | P46095 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10080385 | 0.95 | DDR2 (0.49) | MAPK14DDR2SLC2A1FASNPRKAA2 | |
| SCHEMBL1140453 | 0.94 | DDR2 (0.49) | MAPK14DDR2RETFASNPRKAA2 | |
| SCHEMBL1140460 | 0.93 | DDR2 (0.48) | MAPK14DDR2SLC2A1RETFASN | |
| SCHEMBL1140493 | 0.93 | DDR2 (0.48) | MAPK14DDR2SLC2A1RETFASN | |
| SCHEMBL1140359 | 0.93 | DDR2 (0.53) | MAPK14DDR2RETFASNPRKAA2 | |
| SCHEMBL6343937 | 0.93 | DDR2 (0.47) | MAPK14DDR2SLC2A1RETFASN | |
| SCHEMBL1140351 | 0.91 | HIF1A (0.51) | MAPK14DDR2RETFASNPPARG | |
| SCHEMBL1140297 | 0.91 | FASN (0.49) | MAPK14DDR2SLC2A1FASNPRKAA2 | |
| SCHEMBL1140747 | 0.90 | MAPK14 (0.51) | MAPK14DDR2RETFASNPPARG | |
| SCHEMBL6364860 | 0.89 | DDR2 (0.49) | MAPK14DDR2RETFASNPRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363393-A1 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2011-09-07 | — | — | EP | claimed |
| US-8507471-B2 | Biphenylcarboxamide derivatives as hedgehod pathway modulators | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | disclosed |
| US-8178563-B2 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| EP-2363393-A1 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2011-09-07 | — | — | EP | disclosed |
| US-20110183962-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | NOVARTIS AG (CH) | 2011-07-28 | — | — | US | disclosed |
| EP-2346499-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | Novartis AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| WO-2011062939-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011019798-A1 | METHODS AND COMPOSITIONS FOR TREATING LEUKEMIA | NOVARTIS AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | disclosed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183962-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | GLI1, SHH, SMO | MAPK14 1199/4885DDR2 1123/4885SLC2A1 2030/4885 |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | GLI1, SHH, GLI2 | MAPK14 2353/4885DDR2 1167/4885SLC2A1 1937/4885 |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | MAPK14 1601/4885DDR2 704/4885SLC2A1 1857/4885 |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | MAPK14 1601/4885DDR2 704/4885SLC2A1 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.